MARKET

XGN

XGN

Exagen Inc.
NASDAQ
4.320
+0.120
+2.86%
Opening 11:25 06/09 EDT
OPEN
4.250
PREV CLOSE
4.200
HIGH
4.490
LOW
4.230
VOLUME
51.72K
TURNOVER
--
52 WEEK HIGH
12.23
52 WEEK LOW
2.590
MARKET CAP
104.37M
P/E (TTM)
-4.8885
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XGN last week (0601-0605)?
Weekly Report · 1d ago
Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone
Benzinga · 06/01 13:03
Exagen says systematic review finds AVISE Lupus test flags 25% of SLE cases missed by standard serology
PUBT · 06/01 13:02
Weekly Report: what happened at XGN last week (0525-0529)?
Weekly Report · 06/01 09:16
Weekly Report: what happened at XGN last week (0518-0522)?
Weekly Report · 05/25 09:17
Weekly Report: what happened at XGN last week (0511-0515)?
Weekly Report · 05/18 09:17
Exagen Earnings Call Highlights Growth Amid Key Risks
TipRanks · 05/13 00:39
Exagen (XGN) Q1 2026 Earnings Transcript
NASDAQ · 05/12 18:16
More
About XGN
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Webull offers Exagen Inc stock information, including NASDAQ: XGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XGN stock methods without spending real money on the virtual paper trading platform.